Winolip EZ
Cheaper & Alternative Brands
Same generic (Bempedoic acid + Ezetimibe), same form (Tablet)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Dosage & Administration
Administer Bempedoic Acid 180 mg & Ezetimibe 10 mg tablet orally once daily with or without food. The safety and effectiveness of this tablet have not been established in pediatric patients.
Contraindications
This is contraindicated in patients with a known hypersensitivity to ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash and urticaria have been reported with ezetimibe
Side Effects & Adverse Reactions
Upper respiratory tract infection
Muscle Spasms
Hyperuricemia
Back pain
Abdominal pain or discomfort
Bronchitis
Pain in extremity
Anemia
Elevated liver enzymes
Warnings & Precautions
Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. Tendon rupture has occurred. Discontinue Bempedoic acid & Ezetimibe at the first sign of tendon rupture. Avoid combination in patients who have a history of tendon disorders or tendon rupture.
Pharmacology & Mechanism of Action
Bempedoic Acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowes LDL-C in blood via upregulation of low-density lipoprotein receptors. Ezetimibe is a potent and selective inhibitor of cholesterol absorption that has been shown to reduce the overall delivery of cholesterol to the liver, thereby promoting the synthesis of LDL receptors, with a subsequent reduction of serum LDL-C.